作者
Sameer A Parikh, Eli Muchtar, Betsy Laplant, Wei Ding, Sikander Ailawadhi, Amber Koehler, Timothy G Call, Saad S Kenderian, Jose F Leis, Amie Fonder, Min Shi, Asher A Chanan-Khan, Adam Pettinger, Thomas E Witzig, Carrie A Thompson, Jose C Villasboas, Jessica M Sholes, Curtis A Hanson, Esteban Braggio, Kay L Medina, Susan L Slager, Neil E Kay
发表日期
2019/11/13
期刊
Blood
卷号
134
页码范围
4306
出版商
Content Repository Only!
简介
Background: The 2018 iwCLL guidelines recommend close observation of early stage CLL pts who do not meet indications for therapy (“watch and wait” strategy). Prior attempts at early therapeutic intervention in unselected early-stage CLL pts using alkylating agents such as chlorambucil and chemoimmunotherapy failed to show a significant benefit; and these therapies were associated with substantial toxicities. The introduction of Bruton tyrosine kinase (BTK) inhibitors has revolutionized the treatment landscape of CLL. The German CLL Study group recently presented results of the CLL12 study which demonstrated a significant improvement in event-free survival (EFS) among untreated early stage high risk CLL pts who received ibrutinib compared to placebo (median EFS not reached vs. 47.8 months, respectively; Langerbeins, EHA, 2019). Acalabrutinib is a more selective second-generation BTK inhibitor that …
学术搜索中的文章
SA Parikh, E Muchtar, B Laplant, W Ding, S Ailawadhi… - Blood, 2019